Research Articles | Page 4 | Aplastic Anemia & MDS International Foundation Return to top.

Research Articles

Compiled for your convenience are articles on bone marrow failure research and treatment from the world’s major journals on hematology / oncology.

Article Title Original Publication Date Journal Bone Marrow Disease
Myelodysplastic syndromes: 2014 update on diagnosis, risk-stratification, and management Jan 2014 Am J Hematol myelodysplastic syndromes (MDS)
Calculator-free point-of-care prognostication in myelodysplastic syndromes. Jan 2019 Am J Hematol myelodysplastic syndromes (MDS)
IDH mutations are closely associated with mutations of DNMT3A, ASXL1 and SRSF2 in patients with myelodysplastic syndromes and are stable during disease evolution. Oct 2013 Am J Hematol myelodysplastic syndromes (MDS)
Assessment of Human Antihuman Antibodies to Eculizumab After Long-Term Treatment in Patients With Paroxysmal Nocturnal Hemoglobinuria Dec 2015 Am J Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Real-Life experience with azacitidine in myelodysplastic syndromes according to IPSS cytogenetic profile Jan 2014 Am J Hematol myelodysplastic syndromes (MDS)
Evaluation of revised IPSS cytogenetic risk stratification and prognostic impact of monosomal karyotype in 783 patients with primary myelodysplastic syndromes. May 2013 Am J Hematol myelodysplastic syndromes (MDS)
Impact of eculizumab treatment on paroxysmal nocturnal hemoglobinuria: A treatment versus no-treatment study Dec 2015 Am J Hematol paroxysmal nocturnal hemoglobinuria (PNH)
Impact of comorbidities by ACE-27 in the Revised-IPSS for patients with myelodysplastic syndromes Jan 2014 Am J Hematol myelodysplastic syndromes (MDS)
Targeted next-generation sequencing in myelodysplastic syndromes and prognostic interaction between mutations and IPSS-R Sep 2017 Am J Hematol myelodysplastic syndromes (MDS)
Hypoalbuminemia is an independent prognostic factor for overall survival in myelodysplastic syndromes Aug 2012 Am J Hematol myelodysplastic syndromes (MDS)
Share with addtoany.com.